CuraSen is focused on the development of new treatments for neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease and other related orphan conditions. CuraSen’s drugs are designed to activate certain receptor populations in the brain to compensate for critical neuronal and glial functions that have otherwise been lost due to degeneration, and represent a unique approach in the field. The company is evaluating CST-103 and CST-2032, β2-ARs agonists, in combination with CST-107, a β-AR blocker, in multiple Phase 2 clinical studies. The trials include patients with mild cognitive impairment, Parkinson’s disease with rapid eye movement sleep disorder (PDRBD), Lewy body dementia, and mild cognitive impairment or mild dementia due to either Parkinson’s or Alzheimer’s disease. For more information, please visit www.curasen.com.
